News

News 11.03.2021 Zurich-Schlieren, Switzerland, March 10, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the upcoming presentation of four posters with data supporting three of the company’s immunotherapy programs at the American Academy for...

News 09.03.2021 Zurich-Schlieren, Switzerland, March 09, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and its collaborator Novartis, today announced initial results from its ongoing phase 1 study of its first tri-specific COVID-19 antiviral treatment, ensovibep (MP0420),...

Events, External events
Event date: 24.03.2021 Date: March 24, 2021 Time: 08.00 am Duration: 1 hour After defining what are digital therapeutics (DTx) and how they fit within the broader scope of digital health products, we will look at some examples of this new class of products. Also, we will provide an overview of the current and future market,...

Events, External events
Event date: 22.04.2021 Merck invites you to the Biotech Start-Up Symposium, a free two-day virtual networking event designed specifically for start-up biotech companies on April 22nd and 23rd. Speakers will be discussing topics that range from technical (GMP grade Angiogenic Stem Cell) to growing your company (going from an idea at a university to a...

News 02.03.2021 Schlieren (Zurich), Switzerland, March 2, 2021 – Kuros Biosciences (SIX: KURN) today announced that it has signed sales and distribution agreements for MagnetOs bone graft, covering the Netherlands, Switzerland, Austria, and Finland. These add to an existing agreement in the United Kingdom and Ireland. Kuros has signed a sales agency agreement...